羟氯喹通过靶向内体NADPH氧化酶抑制促炎信号通路
该研究探讨羟氯喹(HCQ)是否靶向内体NADPH氧化酶(NOX),后者参与细胞因子及抗磷脂抗体(aPL)的信号转导。体外实验显示HCQ强烈减少或完全阻止TNFα、IL-1β和aPL诱导的人单核细胞及MonoMac1细胞内体NOX活化,并减少下游基因诱导,机制为抑制NOX2催化亚基gp91phox转位至内体。体内模型中HCQ保护小鼠免于aPL诱导且由NOX2介导的血栓形成。
要点
- HCQ通过抑制NOX2催化亚基gp91phox转位至内体,阻断内体NOX2组装。
- HCQ减少TNFα、IL-1β和aPL诱导的单核细胞内体NOX活化及下游基因表达。
- HCQ在体内保护小鼠免于aPL诱导且由NOX2介导的血栓形成。
核心结论
- HCQ通过干扰内体NOX2组装发挥抗炎及抗血栓作用,可能解释其在风湿病包括APS中的多种有益效应。
研究设计与样本
- 体外实验用TNFα、IL-1β或人单克隆aPL刺激单核细胞及MonoMac1细胞,流式细胞术检测NOX活性,定量RT-PCR检测基因表达,共聚焦激光扫描显微镜活细胞成像。
- 体内实验采用静脉血栓形成模型分析HCQ对NOX诱导信号转导的影响。
主要发现
- HCQ强烈减少或完全阻止TNFα、IL-1β和aPL诱导的人单核细胞及MonoMac1细胞内体NOX活化。
- 上述刺激诱导的下游基因表达被HCQ减少或消除。
- HCQ的作用并非直接干扰激动剂,而是抑制NOX2催化亚基gp91phox转位至内体。
- 体内HCQ保护小鼠免于aPL诱导且由NOX2介导的血栓形成。
临床怎么用
- 该机制提示HCQ可能通过靶向内体NOX2对炎症及促血栓信号通路发挥抑制作用,支持其在SLE、RA、APS等风湿病中的应用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Hydroxychloroquine (HCQ) has been used for decades to treat patients with rheumatic diseases, for example, systemic lupus erythematosus (SLE), rheumatoid arthritis or the antiphospholipid syndrome (APS). We hypothesise that HCQ might target endosomal NADPH oxidase (NOX), which is involved in the signal transduction of cytokines as well as antiphospholipid antibodies (aPL). METHODS: For in vitro experiments, monocytic cells were stimulated with tumour necrosis factor α (TNFα), interleukin-1β (IL-1β) or a human monoclonal aPL and the activity of NOX was determined by flow cytometry. The expression of genes known to be induced by these stimuli was quantified by quantitative reverse transcription PCR. Live cell imaging was performed by confocal laser scanning microscopy. Finally, the effects of HCQ on NOX-induced signal transduction were analysed in an in vivo model of venous thrombosis. RESULTS: HCQ strongly reduces or completely prevents the induction of endosomal NOX by TNFα, IL-1β and aPL in human monocytes and MonoMac1 cells. As a consequence, induction of downstream genes by these stimuli is reduced or abrogated. This effect of HCQ is not mediated by direct interference with the agonists but by inhibiting the translocation of the catalytic subunit of NOX2 (gp91phox) into the endosome. In vivo, HCQ protects mice from aPL-induced and NOX2-mediated thrombus formation. CONCLUSIONS: We describe here a novel mechanism of action of HCQ, that is, interference with the assembly of endosomal NOX2. Since endosomal NOX2 is involved in many inflammatory and prothrombotic signalling pathways, this activity of HCQ might explain many of its beneficial effects in rheumatic diseases including the APS.
引用
- Müller-Calleja N, Manukyan D, Canisius A, et al. Hydroxychloroquine inhibits proinflammatory signalling pathways by targeting endosomal NADPH oxidase. Ann Rheum Dis. 2016. PMID: 27903507. doi:10.1136/annrheumdis-2016-210012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。